Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Subscribe to Pharma in Focus

Sign Up Now

Pharma in Focus is considered essential daily reading in the Australian and NZ pharma industry.

In production for 12 years, it is emailed daily to more than 10,000 pharma industry professionals throughout Australia and NZ.

For just $429.95 a year (plus GST) Pharma in Focus puts you ahead of the game by delivering:

  • Key Aussie & NZ pharma news every working day
  • Daily in-depth features covering all aspects of pharma from drug approvals to employment issues
  • Full coverage and analysis of PBAC, PBS and TGA decisions
  • Ten survey-based white papers per year (total value $1500)

New to Pharma in Focus? Sign up below for your FREE two week trial.

Time to subscribe? Sign up below for your 12 month subscription.

Need multiple licenses? We have great corporate rates. Contact our friendly subscription managers on 02 9939 1881 or admin@pharmainfocus.com.au for our latest prices.

3 Simple Steps

1 Fill in your details below and submit

2 Make your subscription choice

3 Make your payment choice (Credit Card, Direct Deposit or Cheque)

Approvals Action
Gilead's Viread replacement registered
Gilead has won registration for chronic hepatitis B treatment Vemlidy, its replacement drug for Viread in that indication, which will soon be facing generic competition.
Pipeline Monitor
Celgene scores with old and new drugs
Celgene's Revlimid has won an additional indication in the US while the company's potential blockbuster, ozanimod, has enjoyed success in a head-to- had trial against Biogen's Avonex.
Debating Point
Expert games not very convincing
Both sides in the battle over the future of biosimilar prescribing in Australia have been rolling out their foreign experts but it's hard to see how fly-in, fly-out expertise can influence a government facing multiple budget management problems at home.